Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells

References

• Acevedo VD, Ittmann M, Spencer DM. 2009. Paths of FGFR-driven tumorigenesis. Cell Cycle. 8 4: 580–588.
   PubMed Web of Science ®Google Scholar
• Armstrong LC, Bornstein P. 2003. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol. 22 1: 63–71.
   PubMedGoogle Scholar
• Ashton AW, Dawes J, Chesterman CN. 1995. Acidic and basic fibroblast growth factors have comparable effects on the haemostatic function of vascular endothelium. Growth Factors. 12 2: 111–120.
   PubMed Web of Science ®Google Scholar
• Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF. 1999. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res. 5 5: 1041–1056.
   PubMed Web of Science ®Google Scholar
• Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ. 2007. Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol. 31 5: 1127–1132.
   PubMedGoogle Scholar
• Dailey L, Ambrosetti D, Mansukhani A, Basilico C. 2005. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 16 2: 233–247.
   PubMed Web of Science ®Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, Bouck N. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265 5178: 1582–1584.
   PubMedGoogle Scholar
• Darby S, Sahadevan K, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ. 2006. Loss of sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene. 25 29: 4122–4127.
   PubMedGoogle Scholar
• Dejong V, Degeorges A, Filleur S, Ait-Si-Ali S, Mettouchi A, Bornstein P, Binetruy B, Cabon F. 1999. The wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-jun. Oncogene. 18 20: 3143–3151.
   PubMedGoogle Scholar
• Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. 1999. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 18 17: 2755–2761.
   PubMedGoogle Scholar
• Eswarakumar VP, Lax I, Schlessinger J. 2005. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16 2: 139–149.
   PubMed Web of Science ®Google Scholar
• Furthauer M, Lin W, Ang SL, Thisse B, Thisse C. 2002. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat Cell Biol. 4 2: 170–174.
   PubMed Web of Science ®Google Scholar
• Garcia-Maya M, Anderson AA, Kendal CE, Kenny AV, Edwards-Ingram LC, Holladay A, Saffell JL. 2006. Ligand concentration is a driver of divergent signaling and pleiotropic cellular responses to FGF. J Cell Physiol. 206 2: 386–393.
   PubMed Web of Science ®Google Scholar
• Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. 2003. FGF8 isoform b expression in human prostate cancer. Br J Cancer. 88 9: 1432–1438.
   PubMedGoogle Scholar
• Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 87 17: 6624–6628.
   PubMed Web of Science ®Google Scholar
• Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA. 1998. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the drosophila airways. Cell. 92 2: 253–263.
   PubMed Web of Science ®Google Scholar
• Hadari YR, Gotoh N, Kouhara H, Lax I, Schlessinger J. 2001. Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci USA. 98 15: 8578–8583.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86 3: 353–364.
   PubMed Web of Science ®Google Scholar
• Harkonen PL, Laaksonen EI, Valve EM, Solic N, Darbre PD. 1990. Temperature-sensitive mutants for steroid-sensitive growth of S115 mouse mammary tumor cells. Exp Cell Res. 186 2: 288–298.
   PubMedGoogle Scholar
• Heldin CH. 1995. Dimerization of cell surface receptors in signal transduction. Cell. 80 2: 213–223.
   PubMed Web of Science ®Google Scholar
• Hyder SM, Liang Y, Wu J. 2009. Estrogen regulation of thrombospondin-1 in human breast cancer cells. Int J Cancer. 125 5: 1045–1053.
   PubMedGoogle Scholar
• Javerzat S, Auguste P, Bikfalvi A. 2002. The role of fibroblast growth factors in vascular development. Trends Mol Med. 8 10: 483–489.
   PubMedGoogle Scholar
• Lawler J, Detmar M. 2004. Tumor progression: The effects of thrombospondin-1 and -2. Int J Biochem Cell Biol. 36 6: 1038–1045.
   PubMed Web of Science ®Google Scholar
• Lax I, Wong A, Lamothe B, Lee A, Frost A, Hawes J, Schlessinger J. 2002. The docking protein FRS2alpha controls a MAPK-mediated negative feedback mechanism for signaling by FGF receptors. Mol Cell. 10 4: 709–719.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Methods. 25 4: 402–408.
   PubMed Web of Science ®Google Scholar
• Li Q, Ahuja N, Burger PC, Issa JP. 1999. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene. 18 21: 3284–3289.
   PubMedGoogle Scholar
• Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G. 2003. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood. 102 13: 4399–4406.
   PubMedGoogle Scholar
• Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD. 2008. Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells. Cancer Res. 68 17: 7090–7099.
   PubMedGoogle Scholar
• Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. 2001. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene. 20 22: 2791–2804.
   PubMedGoogle Scholar
• Mattila MM, Tarkkonen KM, Seppanen JA, Ruohola JK, Valve EM, Harkonen PL. 2006. Androgen and fibroblast growth factor 8 (FGF8) downregulation of thrombospondin 1 (TSP1) in mouse breast cancer cells. Mol Cell Endocrinol. 253 1–2: 36–43.
   PubMedGoogle Scholar
• McGillicuddy FC, O'Toole D, Hickey JA, Gallagher WM, Dawson KA, Keenan AK. 2006. TGF-beta1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. Vascul Pharmacol. 44 6: 469–475.
   PubMedGoogle Scholar
• Mehta PB, Robson CN, Neal DE, Leung HY. 2001. Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene. 20 38: 5359–5365.
   PubMedGoogle Scholar
• Moran TJ, Gray S, Mikosz CA, Conzen SD. 2000. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res. 60 4: 867–872.
   PubMedGoogle Scholar
• Ohuchi H, Yoshioka H, Tanaka A, Kawakami Y, Nohno T, Noji S. 1994. Involvement of androgen-induced growth factor (FGF-8) gene in mouse embryogenesis and morphogenesis. Biochem Biophys Res Commun. 204 2: 882–888.
   PubMedGoogle Scholar
• Okamoto M, Ono M, Uchiumi T, Ueno H, Kohno K, Sugimachi K, Kuwano M. 2002. Up-regulation of thrombospondin-1 gene by epidermal growth factor and transforming growth factor beta in human cancer cells–transcriptional activation and messenger RNA stabilization. Biochim Biophys Acta. 1574 1: 24–34.
   PubMedGoogle Scholar
• Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL, Mohammadi M. 2006. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 20 2: 185–198.
   PubMedGoogle Scholar
• Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271 25: 15292–15297.
   PubMed Web of Science ®Google Scholar
• Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. 2005. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16 2: 159–178.
   PubMed Web of Science ®Google Scholar
• Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS. 2000. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 60 2: 490–498.
   PubMed Web of Science ®Google Scholar
• Ren B, Yee KO, Lawler J, Khosravi-Far R. 2006. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta. 1765 2: 178–188.
   PubMedGoogle Scholar
• Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. 2005. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci USA. 102 37: 13147–13152.
   PubMedGoogle Scholar
• Ruohola JK, Valve EM, Vainikka S, Alitalo K, Harkonen PL. 1995. Androgen and fibroblast growth factor (FGF) regulation of FGF receptors in S115 mouse mammary tumor cells. Endocrinology. 136 5: 2179–2188.
   PubMedGoogle Scholar
• Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL. 2001. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res. 61 10: 4229–4237.
   PubMedGoogle Scholar
• Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B, Martiny L. 2004. Thrombospondin 1: A multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol. 49 3: 245–258.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K. 1992. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA. 89 19: 8928–8932.
   PubMedGoogle Scholar
• Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M. 1998. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 58 10: 2053–2056.
   PubMed Web of Science ®Google Scholar
• Taraboletti G, Belotti D, Borsotti P, Vergani V, Rusnati M, Presta M, Giavazzi R. 1997. The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. Cell Growth Differ. 8 4: 471–479.
   PubMedGoogle Scholar
• Tikhonenko AT, Black DJ, Linial ML. 1996. Viral myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem. 271 48: 30741–30747.
   PubMedGoogle Scholar
• Valta MP, Tuomela J, Vuorikoski H, Loponen N, Vaananen RM, Pettersson K, Vaananen HK, Harkonen PL. 2009. FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem. 107 4: 769–784.
   PubMedGoogle Scholar
• Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G. 2001. p73 overexpression increases VEGF and reduces thrombospondin-1 production: Implications for tumor angiogenesis. Oncogene. 20 50: 7293–7300.
   PubMedGoogle Scholar
• Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. 2002. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell. 2 6: 473–483.
   PubMedGoogle Scholar
• Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. 2003. Ras modulates myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 3 3: 219–231.
   PubMedGoogle Scholar
• Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL. 2001. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA. 98 8: 4622–4627.
   PubMedGoogle Scholar
• Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM, Brugge JS. 2009. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 69 6: 2244–2251.
   PubMedGoogle Scholar
• Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. 1991. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64 4: 841–848.
   PubMed Web of Science ®Google Scholar
• Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. 2009. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat. 114 1: 85–96.
   PubMed Web of Science ®Google Scholar
• Zhao HY, Ooyama A, Yamamoto M, Ikeda R, Haraguchi M, Tabata S, Furukawa T, Che XF, Zhang S, Oka T. 2008. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil. Cancer Res. 68 17: 7035–7041.
   PubMedGoogle Scholar